Cellular Effects of Selected Unsymmetrical Bisacridines on the Multicellular Tumor Spheroids of HCT116 Colon and A549 Lung Cancer Cells in Comparison to Monolayer Cultures.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Oct 2023
Historique:
received: 05 10 2023
revised: 23 10 2023
accepted: 25 10 2023
medline: 15 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

Multicellular tumor spheroids are a good tool for testing new anticancer drugs, including those that may target cancer stem cells (CSCs), which are responsible for cancer progression, metastasis, and recurrence. Therefore, we applied this model in our studies of highly active antitumor unsymmetrical bisacridines (UAs). We investigated the cellular response induced by UAs in 2D and 3D cultures of HCT116 colon and A549 lung cancer cells, with an additional focus on their impact on the CSC-like population. We showed that UAs affected the viability of the studied cells, as well as their spherogenic potential in the 2D and 3D cultures. Furthermore, we proved that the most promising UAs (C-2045 and C-2053) induced apoptosis in the HCT116 and A549 spheres to a similar, or even higher, extent than what was found in monolayer conditions. Next, we identified the population of the CSC-like cells in the 2D and 3D cultures of the studied cell lines by determining the levels of CD166, CD133, CD44, and EpCAM markers. We showed that the selected UAs affected the CSC-like population in both of the cell lines, and that A549 was affected more profoundly in 3D than in 2D cultures. Thus, the UAs exhibited high antitumor properties in both the 2D and 3D conditions, which makes them promising candidates for future therapeutic applications.

Identifiants

pubmed: 37958764
pii: ijms242115780
doi: 10.3390/ijms242115780
pmc: PMC10649579
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Gdańsk University of Technology
ID : mini-grant no. 036053

Références

Front Immunol. 2020 Aug 07;11:1280
pubmed: 32849491
Eur J Med Chem. 2020 Oct 15;204:112599
pubmed: 32736230
J Med Chem. 2020 Dec 24;63(24):15279-15307
pubmed: 33325699
N Z Med J. 2004 Mar 12;117(1190):U799
pubmed: 15107902
Multidiscip Respir Med. 2013 Oct 05;8(1):65
pubmed: 24094028
ACS Appl Mater Interfaces. 2020 Apr 15;12(15):17276-17289
pubmed: 32208730
Cancer Cell. 2015 Mar 9;27(3):342-53
pubmed: 25759020
Neoplasma. 2014;61(2):153-60
pubmed: 24299311
EMBO J. 2011 Jun 24;30(15):3186-99
pubmed: 21701559
Cancer Res. 2007 Apr 15;67(8):3691-7
pubmed: 17440081
Cell. 2005 Jun 17;121(6):823-35
pubmed: 15960971
Int J Oncol. 2019 Jul;55(1):223-242
pubmed: 31180528
Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5
pubmed: 24502949
Cancer Sci. 2009 Jun;100(6):1040-6
pubmed: 19385971
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
Oncotarget. 2016 Jul 19;7(29):45745-45756
pubmed: 27304190
Cancer Res. 2010 Mar 1;70(5):2030-40
pubmed: 20145155
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
N Engl J Med. 2012 Jun 7;366(23):2171-9
pubmed: 22670903
Sci Rep. 2018 Aug 13;8(1):12042
pubmed: 30104575
Int J Mol Sci. 2022 Mar 11;23(6):
pubmed: 35328482
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
Biochem Biophys Res Commun. 2012 Jul 20;424(1):45-51
pubmed: 22727906
Oncol Rep. 2016 Jan;35(1):13-25
pubmed: 26531053
Front Oncol. 2018 Nov 01;8:497
pubmed: 30443493
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
Cancers (Basel). 2019 Feb 03;11(2):
pubmed: 30717462
Cancer Res. 2005 Dec 1;65(23):10946-51
pubmed: 16322242
Front Cell Dev Biol. 2022 Mar 11;10:752326
pubmed: 35359437
Int J Oncol. 2014 Aug;45(2):651-8
pubmed: 24867356
Cell Stem Cell. 2007 Sep 13;1(3):313-23
pubmed: 18371365
Anticancer Res. 2011 Mar;31(3):921-7
pubmed: 21498714
Pharmaceutics. 2023 Jan 06;15(1):
pubmed: 36678830
Exp Biol Med (Maywood). 2016 May;241(9):939-54
pubmed: 27072562
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Eur J Cardiothorac Surg. 2009 Sep;36(3):446-53
pubmed: 19464919
Molecules. 2022 Jun 21;27(13):
pubmed: 35807234
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Int J Oncol. 2018 Feb;52(2):599-612
pubmed: 29207035
Cancer Sci. 2017 Mar;108(3):283-289
pubmed: 28064442
J Clin Invest. 2008 Jun;118(6):2111-20
pubmed: 18497886
Cell Mol Biol Lett. 2014 Mar;19(1):23-36
pubmed: 24363164
Cancer Res. 2009 Oct 1;69(19):7507-11
pubmed: 19752085
Molecules. 2021 Oct 16;26(20):
pubmed: 34684841
Exp Cell Res. 2012 Aug 1;318(13):1577-85
pubmed: 22487097
Biochem Biophys Res Commun. 2017 Aug 12;490(1):29-35
pubmed: 28576498
Clin Exp Metastasis. 2011 Dec;28(8):751-63
pubmed: 21750907

Auteurs

Jolanta Kulesza (J)

Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdańsk University of Technology, 80-233 Gdańsk, Poland.

Ewa Paluszkiewicz (E)

Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdańsk University of Technology, 80-233 Gdańsk, Poland.

Ewa Augustin (E)

Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdańsk University of Technology, 80-233 Gdańsk, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH